Researchers conducted a small, early-stage study to test whether a combination of three drugs could help prevent cancer from returning after surgery for biliary tract cancer. The study involved 28 patients who had their cancer surgically removed but were at high risk of it coming back. Patients received three medications: envafolimab (given as a shot every three weeks), lenvatinib (taken as a daily pill), and capecitabine (taken as pills on a specific schedule).
After about a year of follow-up, researchers found that the median time patients lived without their cancer returning was about 15.6 months. About 68% of patients were cancer-free at one year, and about 91% were still alive at one year. The treatment had side effects, with 17 patients experiencing treatment-related issues and 8 having more serious side effects, but overall the safety profile was considered manageable.
It's important to understand this was a phase II study, which means it's still in early testing. The study didn't have a comparison group receiving standard treatment or placebo, so we can't say for sure if this combination works better than existing approaches. The study was also small and conducted at just one medical center, which limits how broadly we can apply these results.
While these early results are encouraging for patients with this challenging cancer, much more research is needed. Larger studies with comparison groups will be necessary to determine if this three-drug combination should become a standard treatment option after surgery for biliary tract cancer.
